LabConnect, LLC announces the release of its BioVisualization software platform.
LabConnect, LLC., a leading provider of central laboratory services to the biopharmaceutical industry, announces the release of its BioVisualization software platform.
LabConnect’s BioVisualization is a proprietary and customizable software platform that queries clinical sample database(s) in real time to analyze and provide visual interpretations of a project’s data. This unique platform is designed to quickly generate customizable figures, which can be downloaded and shared among colleagues and incorporated into reporting documents.
“Large, complex datasets generated throughout the course of a clinical trial make finding underlying trends challenging,” said Eric Hayashi, president and CEO. “LabConnect’s BioVisualization tool makes it possible to visualize this data and find greater meaning using fewer resources. This inventive platform creates an opportunity to make critical decisions a lot sooner.”
LabConnect’s white paper, “BioVisualization: Custom Approaches to Enhance Clinical Data Mining,” provides an overview of visual data analysis tools, their benefits and how this technology is being implemented by pharmaceutical companies of all sizes to make critical decisions faster and with lower costs. This informative white paper is now available for download.
“The scale of datasets has become overwhelming, making analysis of this information tedious and resource-draining,” said Hermioni Zouridis, senior scientist of scientific operations at LabConnect. “Unlike pre-programmed platforms, versatile visual data analytics tools enable researchers to generate customizable figures, helping identify trends in study results faster and ultimately making it possible to bring drugs to market sooner.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.